Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Japan. The aim of this trial is to assess the safety and
tolerability of activated recombinant human coagulation factor VII analogue (NN1731,
vatreptacog alfa (activated)) in healthy Japanese male subjects. In addition, the
pharmacokinetics of NN1731 will be examined